Pioneering Longevity Drug Administered to First Human Patient
WHO:
Wired - Life Biosciences, a Boston-based biotech startup, is involved in the trial.
Business Insider - Jerry McLaughlin, CEO of Life Biosciences, commented on the significance of the trial.
Business Insider - David Sinclair, cofounder of Life Biosciences and a Harvard geneticist, is a notable figure in longevity science.
WHAT:
Business Insider - Life Biosciences announced that the first human patient has been dosed with a cellular reprogramming injection designed to reverse age-related diseases.
Wired - The injection was administered into the eyeball of a single person with glaucoma.
Business Insider - The initial FDA trial of ER-100 will include a little under 20 patients.
Nature - The trial will test the activation of three genes to potentially regenerate neurons in the optic nerve, which typically do not regenerate in adults.
Wired - Life Biosciences announced that its first patient has been dosed with a cellular reprogramming injection designed to reverse age-related diseases.
Business Insider - The injection was administered into the eyeball of a single person with glaucoma, and the company did not share any other information about the patient.
Business Insider - If the first human trial is successful, it could usher in a new era of aging therapies aimed at making cells more youthful across the body.
Nature - The trial will test a novel approach that involves turning on three genes that seem to “partially reprogram” old cells, allowing them to behave as if they were young again.
Wired - The first human trial of the ER-100 technology aims to treat glaucoma by rejuvenating cells in the optic nerve.
Business Insider - The trial will include patients with either glaucoma or NAION (non-arteritic anterior ischemic optic neuropathy).
Nature - The trial will test the activation of three genes to potentially regenerate neurons in the optic nerve, which typically do not regenerate in adults.
Wired - The ER-100 technology, which claims to reverse aging in cells, has been tested on a human for the first time.
Business Insider - The first patient has been dosed with a cellular reprogramming injection designed to reverse age-related diseases.
Business Insider - The injection was administered into the eyeball of a single person with glaucoma.
Business Insider - The initial FDA trial of ER-100 will include a little under 20 patients.
WHERE:
Business Insider - Clinics in Boston, New York City, Los Angeles, and Charleston are recruiting patients for the trial.
WHEN:
Business Insider - Over the next six months, scientists will monitor the effectiveness of the technique and any safety issues.
WHY:
Business Insider - The potential for cellular reprogramming includes applications beyond eyesight, such as extending healthy life.
Business Insider - The potential for cellular reprogramming includes applications beyond eyesight, such as extending healthy life.
Business Insider - The trial aims to prove that epigenetic reprogramming can improve how people age in the real world.
Business Insider - The potential for cellular reprogramming includes applications beyond eyesight, such as extending healthy life.
HOW:
Business Insider - Participants in this trial are taking the common antibiotic doxycycline daily to activate the therapy, which acts as an on/off switch for the cellular reprogramming therapy.
Business Insider - Participants in this trial are taking the common antibiotic doxycycline daily to activate the therapy, which acts as an on/off switch for the cellular reprogramming therapy.
Business Insider - The therapy involves a daily pill of doxycycline that acts as an on/off switch for the cellular reprogramming therapy.
Business Insider - The therapy involves a daily pill of doxycycline to activate the cellular reprogramming.
Business Insider - Researchers are using three of the four Yamanaka factors in the therapy, omitting the one most associated with cancer development.
(UPDATED June 10, 2026 06:22 UTC)
Life Biosciences has announced a groundbreaking development, as the first human patient has been dosed with a cellular reprogramming injection aimed at reversing age-related diseases. This injection was administered into the eyeball of a patient with glaucoma as part of an initial FDA trial that will involve just under 20 participants, testing the activation of three genes to potentially regenerate neurons in the optic nerve. Participants will take the common antibiotic doxycycline daily, which acts as an on/off switch for the cellular reprogramming therapy, highlighting the potential applications of this technology beyond eyesight, including extending healthy life.
--
(UPDATED June 9, 2026 23:22 UTC)
Wired - Life Biosciences has announced a significant milestone, as its first patient has been dosed with a cellular reprogramming injection aimed at reversing age-related diseases. The injection, administered into the eyeball of a patient with glaucoma, is part of a trial that tests a novel approach of activating three genes to help old cells behave like younger ones. If successful, this trial could pave the way for new aging therapies, with the potential to extend healthy life beyond just eyesight, as participants take the antibiotic doxycycline daily to activate the therapy.
--
(UPDATED June 9, 2026 17:42 UTC)
A groundbreaking human trial is set to begin for the ER-100 technology, which aims to treat glaucoma by rejuvenating cells in the optic nerve. This trial will include patients suffering from glaucoma or non-arteritic anterior ischemic optic neuropathy, and it will focus on activating three genes to potentially regenerate neurons in the optic nerve, a process that typically does not occur in adults. The therapy will involve a daily pill of doxycycline, which serves as an on/off switch for the cellular reprogramming treatment.
--
(UPDATED June 9, 2026 13:54 UTC)
A Boston-based biotech startup, Life Biosciences, has begun a groundbreaking trial of its ER-100 technology, which claims to reverse aging in cells, marking the first time this treatment has been tested on a human. The initial patient, who has glaucoma, received a cellular reprogramming injection directly into their eyeball, and the trial will include nearly 20 participants across clinics in Boston, New York City, Los Angeles, and Charleston, with scientists monitoring the results over the next six months. This innovative therapy, which involves a daily pill of doxycycline to activate the cellular reprogramming, aims to demonstrate that epigenetic reprogramming can improve aging and potentially extend healthy life beyond just eyesight.